(Q34791820)

4 August 2017

1 reference

title

Gastroesophageal reflux disease--should we adopt a new conceptual framework? (English)

1 reference

gastroesophageal reflux disease

4 August 2017

0 references

author name string

Ronnie Fass

series ordinal

1

1 reference

4 August 2017

Joshua J Ofman

series ordinal

2

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

The American Journal of Gastroenterology

4 August 2017

1 reference

4 August 2017

97

1 reference

4 August 2017

8

1 reference

4 August 2017

1901-1909

1 reference

Changing trends in esophageal cancer: a 15-year experience in a single center

4 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05912.X

Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05912.X

Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05912.X

Nonerosive reflux disease--current concepts and dilemmas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05912.X

Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05912.X

Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05912.X

Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05912.X

Correlation of oesophageal acid exposure with Barrett's oesophagus length

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05912.X

Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05912.X

Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux--the "sensitive oesophagus"

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05912.X

Contribution of central sensitisation to the development of non-cardiac chest pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05912.X

Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05912.X

Maximal acid reflux control for Barrett's oesophagus: feasible and effective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05912.X

Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05912.X

Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05912.X

10.1111/J.1572-0241.2002.05912.X

21 January 2018

Identifiers

DOI

0 references

1 reference